GLP-1 Medication and Breastfeeding: What the Evidence Actually Shows

The label says two different things, depending on the formulation

This is the detail almost every roundup on this topic misses: Wegovy's own FDA label does not treat "semaglutide and breastfeeding" as one question. For the oral tablet, a clinical lactation study found SNAC — the absorption-enhancing ingredient that lets semaglutide survive being swallowed — present in human milk, and because infants may clear SNAC more slowly than adults, the label states plainly that breastfeeding is not recommended during treatment with the tablet. For the subcutaneous injection — the form most women on this medication actually use, and the one that contains no SNAC — the label instead says there are no data on its presence in human milk or its effects on a breastfed infant, and leaves the decision to weighing the drug's benefit against the infant's needs with a clinician. Those are two different regulatory postures for two different products carrying the same drug name, and conflating them is the single most common mistake in what gets written about this topic.

What the newest human data actually found

Because the injection label says "no data," a small 2024 study set out to close that gap directly. Researchers analyzed human milk samples donated by eight women taking subcutaneous semaglutide, collected at several points after a dose. Semaglutide was not detected in any sample above the assay's detection limit, and even using a conservative worst-case estimate, the calculated relative infant dose came out to roughly 1.26% — far below the 10% threshold generally used as a marker of low concern for breastfed infants¹. This is reassuring, first-of-its-kind data, and it is also small: eight women, a handful of timepoints, no data yet on long-term infant growth or development in exposed infants. A newer systematic review of GLP-1 and dual GIP/GLP-1 agonist safety across preconception, pregnancy and lactation reached a similarly cautious conclusion — early signals are reassuring for the injectable forms, but the evidence base remains thin enough that guidelines still default to caution²³.

The postpartum weight question underneath this

Part of why this comes up so often is that postpartum weight retention is a real and common experience, and pregnancy-related weight gain that doesn't resolve on its own carries downstream metabolic risk⁵. A 2025 position statement on obesity across the female reproductive life course frames breastfeeding and postpartum weight management as connected rather than competing goals — the priority during active breastfeeding is protecting milk supply and infant nutrition, with more aggressive weight-loss tools generally deferred until weaning unless a clinician judges otherwise for a specific patient⁵. If you started a GLP-1 before pregnancy or fertility treatment, that same conversation about timing applies again on the way back out.

What this means in practice

If you are currently breastfeeding and considering starting or resuming a GLP-1: know which formulation you're being offered, since the label guidance genuinely differs between the tablet and the injection. Bring the question to both your prescriber and, if you have one, an IBCLC or your pediatrician — this is a three-way decision, not a two-way one, because it involves your infant's exposure as well as your own care. Ask specifically what data the "no data" language is based on, since the newer human milk study is recent enough that not every prescriber will have seen it. And if weight loss can reasonably wait until you've weaned or reduced breastfeeding frequency, that remains the more conservative path the label itself points toward for now — not because the emerging data is alarming, but because it is still early. Broader reviews of GLP-1 and SGLT2 exposure during lactation echo the same message: outcomes in exposed infants have not shown clear harm signals so far, but the studies are small and short, which is a reason for continued caution rather than confidence either way⁴. A related but distinct question — how a maternal T2D drug crosses into milk generally — has been mapped more thoroughly across older diabetes medications, and that broader literature is where a lot of the "probably low transfer" intuition for this drug class comes from⁶. This guide is educational only and not medical advice; talk with your prescriber and, if you have one, a lactation consultant before starting or stopping any GLP-1 medication while breastfeeding.